Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Interest of a Long-term (3 Years) Treatment With Peginterferon Alfa-2b and Ribavirin on Liver Fibrosis in Non-responder Chronic Hepatitis C Patients.
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 372
- 试验地点
- 43
- 主要终点
- Rate of patients with at least a one point improvement in Metavir fibrosis score between the inclusion and the end-of-study liver biopsies.
研究概览
简要总结
Patients with chronic hepatitis C who did not respond to previous antiviral treatment develop liver fibrosis leading to cirrhosis. Maintenance low dose pegylated interferon therapy of fibrosis is currently under investigation in large multicenter trials. The aim of our study is to assess if peginterferon alpha2b plus ribavirin is more efficient than peginterferon alpha2b alone. 454 patients will be randomized between the 2 arms and the efficacy will be assessed, after 3 years of treatment, on Metavir liver fibrosis score improvement.
详细描述
Up to 45% of patients with chronic hepatitis C do not respond to pegylated interferon/ribavirin combination therapy. These patients are prone to develop liver fibrosis leading to cirrhosis and its complications. Interferon has proven to be efficient in liver fibrosis treatment even in case of virological non response. Maintenance low dose pegylated interferon therapy is currently under investigation in large multicenter trials. The aim of our study is to assess wether peginterferon alpha 2 b (0.5 µg/kg/week) plus ribavirin (800-1200 mg according to body weight) is more efficient than peginterferon alpha 2 b alone in a long term 3 years treatment of liver fibrosis. 454 patients, non responders (VHC RNA positive after 24 weeks of treatment or absence of ≥ 2 log HCV RNA drop after 12 weeks of treatment) to a previous peginterferon/ribavirin antiviral treatment will be randomized between the 2 arms, with a double-blind masking of ribavirin. The efficacy will be assessed on Metavir liver fibrosis score improvement between pre and post therapeutic liver biopsy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults over 18
- •With a hepatitis C virus infection (HCV RNA and anti-HCV antibodies in serum)
- •Not responders to a previous antiviral treatment using the interferon plus ribavirin combination
- •With a wash-out of treatment for at least 6 months
- •With an active chronic hepatitis C and a Metavir fibrosis score ≥ 2
- •Serum ALT levels > upper limit of the laboratory on two occasions within 6 months before inclusion
- •Accepting to undergo a liver biopsy at the end of the study
- •Negative pregnancy test for women
- •With a social security cover
- •Written informed consent
排除标准
- •History of hepatic complications
- •History of transplantation
- •History of severe seizures
- •History of severe psychiatric disorders
- •Drug addiction within the last 12 months
- •Associated condition susceptible to be responsible for liver fibrosis
- •Hepatocellular carcinoma
- •Cardiovascular disease unstable under treatment
- •Uncontrolled diabetes
- •Retinopathy
- •Thyroid disease unstable under treatment
- •Epilepsy and/or central nervous system functional disorders
- •Autoimmune disease
- •Regular alcohol consumption
- •Pregnancy, breast-feeding or absence of contraception
- •Haemoglobin <12 g/dl
- •platelets <50000/mm3
- •Neutrophils < 1200/ mm3
- •Severe hepatocellular failure (prothrombin index lower than 60%)
- •Renal failure (creatinine clearance lower than 50 mL/Mn)
- •Associated immunosuppressive drugs, corticosteroids, antiviral drugs (other than study ones)
- •Treatment with drugs likely to have an effect on fibrosis
- •Anticonvulsants
- •Inability to tolerate interferon
研究组 & 干预措施
Randomised PegIFN alfa 2b + ribavirin (RBV) arm
Combination of ribavirin capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
干预措施: Peginterferon alfa-2b (Biological)
Randomised PegIFN alfa 2b + ribavirin (RBV) arm
Combination of ribavirin capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
干预措施: Ribavirin (Drug)
Randomised PegIFN alfa 2b + ribavirin-placebo arm
Combination of ribavirin-placebo capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
干预措施: Peginterferon alfa-2b (Biological)
Randomised PegIFN alfa 2b + ribavirin-placebo arm
Combination of ribavirin-placebo capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
干预措施: Ribavirin-Placebo (Drug)
结局指标
主要结局
Rate of patients with at least a one point improvement in Metavir fibrosis score between the inclusion and the end-of-study liver biopsies.
时间窗: Screen visit and M36
次要结局
- Safety of treatment and quality of life(day0, M6, M12, M24, M36)
- Rate of patients with loss of detectable hepatitis C virus RNA(Day 0 to M36)
- Distribution of the Chevallier fibrosis score(Screen visit and M36)
- Evolution of the area of fibrosis between the inclusion and the end-of -study biopsies(Screen visit and M36)
- Liver elasticity before and after treatment(Screen,M12, M24, M36)
- Evolution of the hepatitis C viral load(Screen to M36)
- Fibrosis serum markers(Screen, day0, M6, M12, M24, M36)
- Frequency of occurrence of hepatic complications and/or liver transplantations(Day 0 to M36)
- Distribution of the Metavir scoring on the end-of-study biopsy(M36)